Last reviewed · How we verify
Cocktail
At a glance
| Generic name | Cocktail |
|---|---|
| Also known as | Normal saline injection, Naropin, Toradol, Sprix, Acuvail |
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib (PHASE1)
- MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia (PHASE1)
- CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease (EARLY_PHASE1)
- Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy (NA)
- Subcutaneous Nitroglycerin to Facilitate Trans-radial Access. (PHASE4)
- A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer (PHASE1)
- Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1 (NA)
- A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cocktail CI brief — competitive landscape report
- Cocktail updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI